---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-021083"
form_type: "8-K"
ticker: "CTNM"
cik: "0001855175"
company_name: "Contineum Therapeutics, Inc."
filed_at: "2024-06-24T23:59:59+00:00"
generated_at: "2026-06-01T02:35:24.978743+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Contineum Therapeutics appoints Sarah Boyce to Board, effective June 24, 2024

## Summary
- Sarah Boyce appointed as Class I director and Chair of Nominating and Corporate Governance Committee.
- Boyce currently President & CEO of Avidity Biosciences (RNA); past roles include Akcea, Ionis, Forest Labs.
- As non-employee director, receives standard compensation including initial option for 29,500 Class A shares.
- Replaces Lori Lyons-Williams as Committee Chair; Lyons-Williams remains a member of the committee.

## SEC filing metadata
- accession: 0001437749-24-021083
- form_type: 8-K
- ticker: CTNM
- cik: 0001855175
- company_name: Contineum Therapeutics, Inc.
- filed_at: 2024-06-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855175/000143774924021083/0001437749-24-021083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855175/000143774924021083/cont20240611_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-021083
- JSON: https://secwatch.observer/filing/0001437749-24-021083.json
- Plain text: https://secwatch.observer/filing/0001437749-24-021083.txt

## Key facts
- Executive change
  Sarah Boyce was appointed as Class I Director and Chair of Nominating and Corporate Governance Committee at Contineum Therapeutics, Inc..
  - Action: appointed
  - Role: Class I Director and Chair of Nominating and Corporate Governance Committee
  source text: On June 21, 2024, the board of directors (the “Board”) of Contineum Therapeutics, Inc. (the “Company”) appointed Sarah Boyce as a member of its Board, effective June 24, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855175/000143774924021083/0001437749-24-021083-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.